Back to Search
Start Over
NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions.
- Source :
- Diabetes, Obesity & Metabolism; Sep2017 Supplement S1, Vol. 19, p95-106, 12p
- Publication Year :
- 2017
-
Abstract
- Diabetes mellitus is characterized by chronically elevated blood glucose levels accelerated by a progressive decline of insulin-producing β-cells in the pancreatic islets. Although medications are available to transiently adjust blood glucose to normal levels, the effects of current drugs are limited when it comes to preservation of a critical mass of functional β-cells to sustainably maintain normoglycemia. In this review, we recapitulate recent evidence on the role of pancreatic N-methyl-D-aspartate receptors (NMDARs) in β-cell physiology, and summarize effects of morphinan-based NMDAR antagonists that are beneficial for insulin secretion, glucose tolerance and islet cell survival. We further discuss NMDAR-mediated molecular pathways relevant for neuronal cell survival, which may also be important for the preservation of β-cell function and mass. Finally, we summarize the literature for evidence on the role of NMDARs in the development of diabetic long-term complications, and highlight beneficial pharmacologic aspects of NMDAR antagonists in diabetic nephropathy, retinopathy as well as neuropathy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14628902
- Volume :
- 19
- Database :
- Complementary Index
- Journal :
- Diabetes, Obesity & Metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 125027112
- Full Text :
- https://doi.org/10.1111/dom.13017